Microscopic polyangiitis is an inflammatory disorder that leads to the damage of organs such as kidneys, lungs, skin, joints, and nerves. The disease can be symptomatized by weight loss, inflammation of the kidneys, skin lesions, fever, nerve damage, skin rash, muscle and joint pain, loss of sensation, seizures, abdominal pain, and cough. However, the cause of microscopic polyangiitis is unknown, but it is thought that the overactive immune system causes the inflammation in the tissues and blood vessels. The Chiba University is in the process of developing glucocorticoids for the treatment of microscopic polyangiitis. ChemoCentryx, Inc. is also in the process of developing avacopan (CCX168) as a C5a receptor antagonist for the treatment of microscopic polyangiitis. Some of the companies having the pipeline of microscopic polyangiitis include Amgen plc, ChemoCentryx, Inc., and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.